found that in patients newly diagnosed with FIGO stage II to IV ovarian cancer, serum CA‐125 levels at 3 months after completing primary treatment were the most accurate indicators of overall survival at 24, 36, and 48 months. Here, MUC16 is linked to ovarian carcinoma.